Related Experiment Video
Updated: Sep 28, 2025
08:10
An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
Published on: January 25, 2019
7.9K
Reversible Retinopathy Associated with Fibroblast Growth Factor Receptor Inhibitor
Saagar N Patel1, Mona L Camacci1, Esther M Bowie1
1Department of Ophthalmology, Penn State College of Medicine, Hershey, Pennsylvania, USA.
Case Reports in Ophthalmology
|March 30, 2022
Summary
A patient taking erdafitinib developed reversible pseudovitelliform lesions. Vision improved and lesions resolved after discontinuing this pan-fibroblast growth factor receptor inhibitor.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Pembrolizumab (PD-1 inhibitor) and erdafitinib (pan-fibroblast growth factor receptor inhibitor) are used in cancer treatment.
- Drug-induced ocular side effects can impact patient vision and require careful monitoring.
Observation:
- A 61-year-old patient experienced metamorphopsia (distorted vision) lasting 3 days.
- Ophthalmic examination revealed bilateral pseudovitelliform macular lesions 6 weeks after starting erdafitinib therapy.
Findings:
- The patient's visual complaints and pseudovitelliform lesions resolved after discontinuing erdafitinib.
- Optical coherence tomography confirmed the decrease in macular lesions.
Implications:
- This case highlights the potential for erdafitinib to cause reversible macular abnormalities.
- Early recognition and drug discontinuation may prevent persistent visual impairment.
- Further research is needed to understand the mechanism and incidence of these ocular side effects.
